Latest News

dvaxis Adds 6% on Updated Data from a Phase 2 Study of AXAL in Advanced Cervical Cancer Showing Promising Survival Rates Consistent with Earlier Reports

Advaxis (ADXS) gains 6% after the company says additional preliminary data will be presented from a two-stage Phase 2 study of its lead immunotherapy candidate, axalimogene filolisbac (AXAL), in patients with persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC) who have progressed on at least one prior line of systemic therapy. At a median follow-up[Read More…]

by June 6, 2016 0 comments Business

Celldex Therapeutics Reports Positive Results from Phase 2 Clinical Study of Malignant Melanoma Treatment

Celldex Therapeutics (CLDX), a biopharmaceutical company, reported Monday promising results from a Phase 2 clinical study evaluating CDX-1401 and CDX-301 in patients with malignant melanoma, which was conducted by the Cancer Immunotherapy Trials Network (CITN) under a Cooperative Research and Development Agreement (CRADA) between Celldex and the Cancer Therapy Evaluation Program of the National Cancer Institute. CDX-1401 is an NY-ESO-1-antibody[Read More…]

by June 6, 2016 0 comments Momentum Stocks

BBCN Bancorp Inc (NASDAQ:BBCN) Issues Note to Investors

Several analysts have recently weighed in on BBCN Bancorp Inc (NASDAQ:BBCN), issuing notes to investors. Julianna Balicka of Keefe, Bruyette & Woods released a note on the stock 2 ago with a $16.00 price target. “BBCN is continuing to make progress in its strategy of winning banking business from U.S.-based subsidiaries of South Korean companies. As of June 30, BBCN[Read More…]

by October 25, 2015 0 comments Analyst Research, Business, Featured, Living

Analysts Views Mixed on Barnes & Noble, Inc. (BKS)

Several analysts have recently weighed in on Barnes & Noble, Inc. (NYSE:BKS), issuing notes to investors. Paul J. Miller of FBR Capital Markets issued a note on the stock on 29th July with a $21.00 price target. “We reiterate our Market Perform rating and $21 price target on shares of State Bank following 2Q15 earnings. This was another solid operating[Read More…]

by October 14, 2015 0 comments Living

Analysts Optimistic on BGC Partners, Inc. (NASDAQ:BGCP)

Several analysts have recently weighed in on BGC Partners, Inc. (NASDAQ:BGCP), issuing notes to investors. Richard Repetto of Sandler O’Neill released a note with Buy rating on the stock 29th July with a $12.50 price target. “Distributable earnings for BGCP beat us and consensus. BGC Partners reported 2Q15 distributable earnings per share of $0.18, which was above our estimate and[Read More…]

by October 14, 2015 0 comments Business

Analysts Views Mixed on Bonanza Creek Energy Inc (BCEI)

Several analysts have recently weighed in on Bonanza Creek Energy Inc (NYSE:BCEI), issuing notes to investors. From them David Meats of Morning Star issued a note on the stock on 29th July with a $8.96 price target. “The sharp reduction in our Bonanza Creek Energy fair value estimate is not a reaction to a disastrous quarter. In fact, the firm[Read More…]

by October 14, 2015 0 comments Momentum Stocks

Analysts Views Mixed on Basic Energy Services, Inc (BAS)

Several analysts have recently weighed in on Basic Energy Services, Inc (NYSE:BAS), issuing notes to investors. James West of Evercore ISI released Buy rating on the stock 2month ago with a $9.00 price target, or 49.01% Upside to the last closing price. “We believe shares have significant room to run after the stock retraced March lows. While we have espoused[Read More…]

by October 14, 2015 0 comments Business

Analysts Strong on CalAmp Corp. (NASDAQ:CAMP)

Several analysts have recently weighed in on CalAmp Corp. (NASDAQ:CAMP), Mike Crawford of B. Riley & Co., LLC raising estimates and maintaining positive outlook with their Buy rating on the stock on Oct 02 2015 with a $32.50 price target, or 107.67% upside to the last closing price. CAMP shares traded up 11% (to $17.40 at last check) after reporting[Read More…]

by October 13, 2015 0 comments Science

Analysts Optimistic on Callidus Software Inc. (NASDAQ:CALD)

Several analysts have recently weighed in on Callidus Software Inc. (NASDAQ:CALD), Eric Martinuzzi of Lake Street Capital Market gives a Buy rating on the stock on July 31 st 2015 with a $19.00 price target, or 27.26% upside to the last closing price. Growth Over Income – Callidus had a successful Q2, with normalized bookings up 46%. Rather than take[Read More…]

by October 13, 2015 0 comments Momentum Stocks

Analysts Views Mixed on Boston Private Financial Hldg Inc (NASDAQ:BPFH)

Several analysts have recently weighed in on Boston Private Financial Hldg Inc (NASDAQ:BPFH) issuing notes to investors. Jennifer H. Demba of SunTrust Robinson reiterated their Buy rating on the stock 3 month ago with a $15.00 price target, or 13.81% Upside to the last closing price. “BPFH reported 2Q15 EPS of $0.20, which was above consensus and STRH expectations of[Read More…]

by October 13, 2015 0 comments Business